New understanding of tiny RNA molecules could have far-ranging medical applications. A screen for morphological complexity identifies regulators of switch-like transitions between discrete cell shapes. Alnylam Presents New Pre-clinical Data on ALN-AT3, an RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders. Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting.
Study shows miR-22 plays a key role in both breast cancer and blood cancer. Development of a novel adenovirus–alphavirus hybrid vector with RNA replicon features for malignant hematopoietic cell transduction. Correctly Reading DNA to make RNA, backward and forward. MIT Press Release: MIT biologists have discovered a mechanism that allows cells to read their own DNA in the correct direction and prevents them from copying most of the so-called “junk DNA” that makes up long stretches of our genome.
Only about 15 percent of the human genome consists of protein-coding genes, but in recent years scientists have found that a surprising amount of the junk, or intergenic DNA, does get copied into RNA — the molecule that carries DNA’s messages to the rest of the cell. Scientists have been trying to figure out just what this RNA might be doing, if anything. In 2008, MIT researchers led by Institute Professor Phillip Sharp discovered that much of this RNA is generated through a process called divergent expression, through which cells read their DNA in both directions moving away from a given starting point.
Graduate students Albert Almada and Xuebing Wu are the lead authors of the paper. Choosing direction A widespread phenomenon. Symptoms of Prader-Willi syndrome associated with interference in circadian, metabolic genes. Mirna Therapeutics and Horizon Discovery Publication Elucidates Novel miR-34 Tumor Suppressor Pathway, Underscores miR-34 as Important Anticancer Approach. Alnylam's 5x15 Progress Report. Printed From BioPortfolio.com By RNA interference drug development Alnylam Pharmaceuticals (ALNY) is a Cambridge, Massachusetts company focused on the development and commercialization of novel RNAi therapeutics for the treatment of diseases with high unmet medical need and genetically defined targets.
Alnylam expects to have five RNAi programs in clinical development, or in commercial stages, by the end of 2015. The company's core product strategy, called "Alnylam 5x15", involves developing all five program candidates with the following shared characteristics: Specificity for genetically defined target and disease. On June 13, the company presented at the Goldman Complete Story » Original Article: Alnylam's 5x15 Progress Report More From BioPortfolio on "Alnylam's 5x15 Progress Report" Advertisement. Explainer: what is RNA? By Merlin CrossleyOur genetic material is encoded in DNA (deoxyribonucleic acid).
DNA is famous. But you may also have also heard of RNA (ribonucleic acid). So, what is RNA, and what is it good for? Quite a lot really. In fact, it is possible that early life used RNA as its genetic material and also used folded RNAs as chemical tools to survive. You might think that being unstable is a bad thing, but there are advantages. The role of microRNAs in the tumorigenesis of ovarian cancer. Alnylam Reports Positive Phase II Data for ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR) LGC invests in US genomics laboratory expansion and initiates nucleic acid extraction service to customers in North America.
DNA and RNA extraction services will complement existing genotyping service and allow improved research and development support to North American researchers January 15th 2012: LGC has announced the expansion of its nucleic acid extraction service capacity into North America.
The extraction service will complement existing capacity in Berlin and London, and will be delivered from the group’s genomics laboratory in Beverly, MA – north of Boston. LGC Genomics has substantial experience in the nucleic acid extraction field, offering not only outsourcing options for a global customer base but also reagents and instrumentation for laboratories who wish to run their extraction work in-house. With a range of proprietary Nucleic Acid Extraction technologies, including the sbeadex® and KleargeneTM ranges, along with instruments that enable automation, LGC Genomics is well positioned to support both large and small scale research projects. www.lgcgroup.com The portfolio includes:
BioPortfolio - the Biotechnology, Pharmaceutical, Life-Science and Healthcare Portal. Researchers find RNA molecule that interferes with lipoprotein production, reduces hyperlipidemia. Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases. Comprehensive molecular characterization of clear cell renal cell carcinoma. TotalScript™ RNA-Seq kits, supplied by Cambio, create libraries from 5 ng total RNA. Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China. Study offers hope for development of novel treatments for stroke, neurological diseases. Integrated molecular analysis of clear-cell renal cell carcinoma. Promoter directionality is controlled by U1 snRNP and polyadenylation signals.